#United Kingdom #Oxford #Brainomix #ERS Congress #ILD

Brainomix Presents Groundbreaking Research at ERS Congress 2026

In a significant step for medical imaging, Brainomix, a pioneering company in AI-powered imaging solutions for stroke and lung diseases, is gearing up to unveil five innovative studies focusing on the utility of quantitative CT analysis in understanding Interstitial Lung Disease (ILD). These presentations will take place at the European Respiratory Society (ERS) Congress 2026, scheduled for September 5-9 in Barcelona, Spain.

The highlighted studies will showcase Brainomix's advanced imaging technology, particularly its e-Lung platform, known for its ability to provide automatic quantification and detailed visualizations of lung CT scan features. This FDA-cleared and CE-marked imaging tool stands to revolutionize the diagnostic strategies employed by clinicians, offering insight into lung diseases that could lead to improved patient outcomes.

The Studies at a Glance

The five studies that will be featured during the congress build upon Brainomix's legacy of clinical evidence. The insights revealed through these presentations are intended to assert the promising role of quantitative imaging in the patient journey dealing with fibrotic lung diseases. Here’s a brief overview of each study:

1. Treatment with taladegib results in increased lung volume and regression of markers of ILD
Presenter: Prof. Peter George (London, UK)
Date/Time: Sunday, September 6, 8:00 - 9:30 AM CEST
This study demonstrates that taladegib treatment enhances lung capacity and reduces ILD markers.

2. Telomere shortening is associated with quantitative CT reticulovascular burden and mortality in fibrotic ILD
Presenter: Prof. Ayodeji Adegunsoye (Chicago, USA)
Date/Time: Sunday, September 6, 8:00 - 9:30 AM CEST
This research correlates shortened telomeres with the severity of lung fibrosis and mortality risks.

3. Validation of e-Lung quantitative CT risk thresholds in fibrotic interstitial lung disease
Presenter: Prof. Peter George (London, UK)
Date/Time: Sunday, September 6, 8:00 - 9:30 AM CEST
The study aims to validate new risk thresholds for ILD based on quantitative CT results.

4. Early change in quantitative CT biomarkers is associated with future FVC decline in patients with progressive pulmonary fibrosis
Presenter: Prof. Peter George (London, UK)
Date/Time: Tuesday, September 8, 12:30 - 2:00 PM CEST
Findings indicate that early changes in CT biomarkers can forecast future declines in lung function.

5. Assessment of e-Lung quantitative CT biomarkers of pulmonary fibrosis in IPF patients with and without pulmonary hypertension
Presenter: Dr. Sophie Herbert (London, UK)
Date/Time: Tuesday, September 8, 12:30 - 2:00 PM CEST
This study evaluates the role of e-Lung biomarkers in assessing pulmonary fibrosis among patients with different risk profiles.

The Impact of AI in Health Care

The significance of this research cannot be understated. Prof. Peter George, a consultant pulmonologist and senior medical director at Brainomix, emphasizes that these findings serve to underline the potential of quantitative CT. By allowing for better assessment of treatment responses, early detection of disease progression, and improved patient stratification in terms of risk factors, these imaging biomarkers can significantly transform clinical practice approaches to ILD.

With the capacity to provide objective insights, Brainomix's imaging technology could complement traditional clinical measures, encouraging more precise and tailored therapeutic strategies — a much-needed evolution in managing complex lung diseases.

About Brainomix

Founded as a spinout from the University of Oxford, Brainomix has quickly established itself as a leader in AI medical imaging. Its flagship product, the Brainomix 360 Stroke, is a fully automated imaging platform that revolutionizes stroke assessments at various stages. With operations expanding across more than 20 countries, the company is at the forefront of facilitating better treatment decisions in lung diseases through technology. Interested individuals can learn more about Brainomix and its innovative solutions by visiting www.brainomix.com.

Overall, Brainomix’s presentations at the ERS Congress are anticipated to spark dialogues around the integration of advanced imaging technologies in pulmonary care, emphasizing the importance of innovation in the medical field.